Stock VTGN VISTAGEN THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Vistagen Therapeutics, Inc.

Equities

VTGN

US92840H4002

Market Closed - Nasdaq
Other stock markets
 04:00:03 2024-05-31 pm EDT 		5-day change 1st Jan Change
3.865 USD -0.64% Intraday chart for Vistagen Therapeutics, Inc. -5.27% -24.81%
May. 23 Vistagen Therapeutics, Inc. to Present At the 2024 American Society of Clinical Psychopharmacology Conference CI
Apr. 25 Vistagen Announces Positive Results from Phase 2A Pilot Study of Ph15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue CI

Evolution of the average Target Price on Vistagen Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

afff17cc46a97d99275f336b11be102.ftWs33uC0z0pd_G5lnRFk1VJsHGdwPOAwO-jjJm8Vuc.Cbf9qT7IqnVlNqeN2Bshphkb2AjRk7fCt4HzuszXFaMMmpy7C9uEWWJGpA~a941a10a745d037b94f0c76f317affbb

Analyst Recommendations on Vistagen Therapeutics, Inc.

Jefferies Upgrades VistaGen Therapeutics to Buy From Hold, Raises Price Target to $15 From $6 MT
Stifel Starts VistaGen Therapeutics With Buy Rating, $12 Price Target MT
Maxim Cuts Price Target on VistaGen Therapeutics to $12 From $30, Maintains Buy Rating MT
Rate hike fears return with a vengeance Our Logo
Maxim Downgrades VistaGen Therapeutics to Hold From Buy MT
Jefferies Downgrades VistaGen Therapeutics to Hold from Buy, Adjusts Price Target to $0.20 from $8 MT
William Blair Downgrades VistaGen Therapeutics to Market Perform From Outperform MT
VISTAGEN THERAPEUTICS : Baird Starts VistaGen Therapeutics at Outperform With $9 Price Target MT
VISTAGEN THERAPEUTICS : Jefferies Starts VistaGen Therapeutics at Buy with $6 Price Target MT
VISTAGEN THERAPEUTICS : William Blair Upgrades VistaGen Therapeutics to Outperform From Market Perform MT
VISTAGEN THERAPEUTICS : Maxim Adjusts Price Target on VistaGen Therapeutics to $5 From $3, Reiterates Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.86 USD
Average target price
13.25 USD
Spread / Average Target
+243.26%
High Price Target
15 USD
Spread / Highest target
+288.60%
Low Price Target
12 USD
Spread / Lowest Target
+210.88%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Vistagen Therapeutics, Inc.

Jefferies & Co.
Stifel Nicolaus
Maxim
William Blair & Co.
Baird

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. VTGN Stock
  4. Consensus Vistagen Therapeutics, Inc.